Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Anesthesiology
    • Alteplase cuts...

    Alteplase cuts long-term mortality risk in Acute ischaemic stroke

    Written by Vinay Singh singh Published On 2018-10-26T19:10:42+05:30  |  Updated On 26 Oct 2018 7:10 PM IST
    Alteplase  cuts long-term mortality risk in Acute ischaemic stroke
    Alteplase cuts long-term mortality risk in Acute ischaemic stroke,according to a new study.

    The study published in the Journal of Stroke & Cerebrovascular diseases reports that intravenous (IV) Alteplase, recombinant tissue-type plasminogen activator (rt-PA) is associated with reduced long-term mortality in acute ischemic stroke patients.


    Bin Qin et al. performed a systematic review and meta-analysis to evaluate all available evidence from the real-world observational trials about long-term outcomes of treatment with intravenous recombinant tissue-type plasminogen activator compared with not treated with IV recombinant tissue-type plasminogen activator (non-rt-PA) in patients with acute ischaemic stroke.


    Read Also: Mediterranean Diet reduces stroke risk among women
    The investigators extracted the data from Pubmed and Embase containing observational studies reporting matched or adjusted results comparing IV rt-PA versus non-rt-PA in patients with acute ischaemic stroke. The major outcomes measured included all-cause mortality, hospital readmission rates, and independence rates. The authors included six observational trials with 16,399 participants.


    The analysis revealed that the use of IV rt-PA in acute ischaemic stroke patients was associated with a lower risk of mortality and there was no heterogeneity across trials. The authors also found that there was no evidence of an effect on hospital readmission rates and independence rates.


    The authors concluded that the findings of the meta-analysis are reassuring clinicians concerned about the effect of recombinant tissue-type plasminogen activator on patient survival, readmission, and independence.


    Read Also: CT Angio improves survival in stroke patients: Lancet
    “Further much-needed evidence is warranted to reassure clinicians and patients about the long-term benefits of IVrtPA treatment following current guidelines, ”write the authors.


    Ischemic stroke occurs due to a sudden loss of blood circulation to an area of the brain which causes a corresponding loss of neurologic function. Acute ischemic stroke is characterized by thrombotic or embolic occlusion of a cerebral artery and is more common than hemorrhagic stroke.


    For reference log on to https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.08.015


    Bin QinhemorrhagicintravenousischemicJournal of Stroke & Cerebrovascularlongmortalityneurologicplasminogenrecombinantstroketermtissue
    Source : With inputs from Journal of Stroke & Cerebrovascular

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok